• Merck KGaA won European Commission clearance to expand Erbitux use in BRAF V600E-mutant metastatic colorectal cancer, including first-line therapy.
• Label now covers Erbitux with encorafenib plus FOLFOX in previously untreated patients, positioning a targeted regimen at treatment start.
• BREAKWATER Phase 3 results showed median overall survival of 30.3 months vs 15.1 months; hazard ratio 0.49.
• Median progression-free survival reached 12.8 months vs 7.1 months; hazard ratio 0.53.
• Erbitux with encorafenib also gained EU use in previously treated patients, supported by BEACON overall survival of 9.3 months vs 5.9 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.